A new study from researchers at the University of Cincinnati (UC) challenges the conventional view that newly approved monoclonal antibody Alzheimer’s drugs primarily work by clearing amyloid plaques. The research indicates that increases in a critical brain protein, rather than reductions in amyloid plaques, might be contributing to the slowing…

RNA therapeutics specialist Alnylam reports positive Phase III results for its RNA interference (i) therapy vutrisiran for treatment of the heart condition transthyretin amyloid cardiomyopathy (ATTR-CM). There are different types of amyloidosis, where abnormal proteins build up in different organs around the body. People with ATTR-CM have a build up…

Icahn School of Medicine at Mount Sinai researchers report that they have identified a novel method to potentially slow or even halt progression of Alzheimer’s disease (AD) by manipulating cellular interactions of protein around myeloid plaques. The new findings, published in the journal Nature Neuroscience, focuses on the role of…

A key mechanism that may explain the clearance of amyloid protein via multisensory gamma stimulation has been uncovered. Researchers at the Massachusetts Institute of Technology (MIT) say they discovered  a “plumbing” network parallel to the brain’s blood vessels that does this. The study appeared in Nature yesterday, the first author is Mitch…

A fluorescent coumarin-based, two-sensor array correctly discriminates between four different amyloids implicated in amyloid-related pathologies with 100 percent classification, according to research from an Australian team. Their work was published in ACS Sensors, and the lead author is Natalie Trinh of the University of Sydney. One of the biggest challenges…

Amyloid disease therapy and diagnostic company AltPep announced today it has completed a $52.9 million Series B financing round that will help further its efforts to develop Alzheimer’s disease and Parkinson’s disease treatments and diagnostics. The proceeds from the investment, led by Senator Investment Group, LP, will be used to…

Researchers, led by a team at the Pompeu Fabra University (UPF) in Barcelona, Spain, have identified new genes that modulate the toxicity of β-amyloid, the protein that is largely responsible for the development of Alzheimer’s disease. In total, the study identifies 238 genes that either provide protection or increase the…

White individuals with Alzheimer’s disease appear to be more likely to have signs of amyloid plaques on brain scans using positron emission tomography (PET) than people from Black, Hispanic, and Asian populations, shows research led by Vanderbilt University. These findings may impact treatment efficacy. This is because new anti-amyloid monoclonal…

U.S. biopharma Attralus this week reported promising findings at a scientific meeting in Germany for its therapies targeting systemic amyloidosis, a diverse group of debilitating diseases involving the build-up of amyloid in vital organs.   The findings, presented at this year’s International Symposium on Amyloidosis in Heidelberg, cover clinical and…

New research into Alzheimer’s disease (AD) treatment by a team led by Claudio Soto, PhD, professor in the Department of Neurology with McGovern Medical School at UTHealth Houston has shown in a mouse study that a whole exchange of blood decreased the formation in the brain of amyloid plaque. The…

Researchers have tried to uncover the how a key biological molecule self assembles into a rogue protein-like substance—amyloid—which is thought to play a role in the development of type-2 diabetes (T2D). Now, scientists from the University of Leeds report they have been able to identify the step-by-step changes that take…

A new mouse study by a team co-led by scientists at Scripps Research has demonstrated how the production of amyloid beta Aβ in the brain is tightly regulated by cholesterol and how this early toxic event plays a role in the pathogenesis of Alzheimer’s disease (AD). Their findings are published…

Transactive response DNA-binding protein-43 (TDP-43) is a soluble protein that interacts with nucleic acids. However, in several neurodegenerative disorders, this protein forms large, harmful rope-like clumps. These abnormal structures, known as amyloid fibrils, are a signature of brain pathology in amyotrophic lateral sclerosis (ALS). Similar inclusions have also been found…

Although there have been many studies done, there remain many questions on the exact Amyloid-beta (Aβ) form responsible for neurotoxicity in Alzheimer’s Disease. Now researchers have revealed for the first time the atomic structure of Aβ protein assemblies. Their study, “Aβ(1-42) tetramer and octamer structures reveal edge conductivity pores as…

The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) prevention study was created in 2014 to test whether the monoclonal antibody drug solanezumab reduces cognitive decline if given to individuals with elevated amyloid levels before signs of the disease are apparent. In its first publication, the group’s findings support the idea…